A Placebo-Controlled, Multicentre, Randomised, Parallel Group, Phase IV Trial to Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) Chinese Patients Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Front Line Standard Platinum-Based Chemotherapy.

Trial Profile

A Placebo-Controlled, Multicentre, Randomised, Parallel Group, Phase IV Trial to Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) Chinese Patients Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Front Line Standard Platinum-Based Chemotherapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms INFORM
  • Sponsors AstraZeneca
  • Most Recent Events

    • 27 Sep 2011 Results presented at the 2011 European Multidisciplinary Cancer Congress.
    • 07 Jul 2011 Results presented at the 14th Annual Congress of the European Respiratory Society.
    • 05 Jun 2011 Results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top